期刊
SURGERY TODAY
卷 51, 期 11, 页码 1736-1754出版社
SPRINGER
DOI: 10.1007/s00595-020-02222-0
关键词
Conversion surgery; Stage IV gastric cancer; Induction chemotherapy
类别
With advances in gastric cancer chemotherapy, multimodal treatment including perioperative chemotherapy plus conversion surgery has become a new strategy for treating stage IV gastric cancer patients. Conversion surgery aims to achieve R0 resection after a good response to induction chemotherapy for initially unresectable tumors.
Palliative chemotherapy with best supportive care is a mainstay for patients with gastric cancer (GC) and distant metastasis. However, with advances in GC chemotherapy, multimodal treatment, including perioperative chemotherapy plus conversion surgery, has attracted attention as a new strategy to improve the outcome of patients with stage IV disease. Conversion surgery is defined as surgical treatment aimed at R0 resection after a good response to induction chemotherapy for tumors originally considered unresectable or marginally resectable for technical and/or oncological reasons. Various biological characteristics differ, depending on each metastatic condition in stage IV GC. The main metastatic pathways of GC can be divided into three categories: lymphatic, hematogenous, and peritoneal. In each category, considerable historical data on conversion surgery have demonstrated the benefits of individualized approaches. However, owing to the diversity of these conditions, a common definition, including the choice of induction chemotherapy, optimal timing of resection, and eligibility for conversion surgery, has not been established among surgical oncologists. Thus, we explore the current and future treatment options by reviewing the literature on this controversial topic comprehensively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据